SEQIRUS for SEQIRUS
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2023 | $190,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Oct 20, 2023 | $220,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY2024 Appropriations and supplemental appropriations; H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022; Pandemic and All-Hazards Preparedness Reauthorization; Department of Defense and Veterans Administration acquisition of influenza vaccine
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Health Issues HCR
Issues related to seasonal and pandemic influenza preparedness.
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.